Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Nelson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|November 3, 2017
Determining Brain Death: Basic Approach and Controversial IssuesAngela Nelson, Ariane Lewis
Archives of Biochemistry and Biophysics|August 21, 2012
Proconvertase proteolytic processing of an enzymatically active myeloperoxidase precursorSally McCormick, Angela Nelson, William M Nauseef
Journal of the National Cancer Institute|November 12, 2024
Supporting evidence in phase 2 cancer trial protocols: a content analysisSelin Bicer, Angela Nelson, Katerina Carayannis, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 2, 2004
Cognitive therapy for command hallucinations: randomised controlled trialPeter Trower, Max Birchwood, Alan Meaden, et al.
The Journal of Pediatrics|September 1, 2023
Timing for First-in-Minor Clinical Trials of New Cancer DrugsSelin Bicer, Nora Hutchinson, Emma Feldhake, et al.
Beilstein Journal of Organic Chemistry|January 23, 2008
Facile synthesis of two diastereomeric indolizidines corresponding to the postulated structure of alkaloid 5,9E-259B from a Bufonid toad (Melanophryniscus)Angela Nelson, H Martin Garraffo, Thomas F Spande, et al.
Journal of Clinical Epidemiology|January 21, 2026
Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trialsAngela Nelson, Hannah Moyer, Karine Vigneault, et al.
Journal of Clinical Epidemiology|April 7, 2023
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trialsHannah Moyer, Merlin Bittlinger, Angela Nelson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|November 3, 2017
Determining Brain Death: Basic Approach and Controversial IssuesAngela Nelson, Ariane Lewis
Archives of Biochemistry and Biophysics|August 21, 2012
Proconvertase proteolytic processing of an enzymatically active myeloperoxidase precursorSally McCormick, Angela Nelson, William M Nauseef
Journal of the National Cancer Institute|November 12, 2024
Supporting evidence in phase 2 cancer trial protocols: a content analysisSelin Bicer, Angela Nelson, Katerina Carayannis, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 2, 2004
Cognitive therapy for command hallucinations: randomised controlled trialPeter Trower, Max Birchwood, Alan Meaden, et al.
The Journal of Pediatrics|September 1, 2023
Timing for First-in-Minor Clinical Trials of New Cancer DrugsSelin Bicer, Nora Hutchinson, Emma Feldhake, et al.
Beilstein Journal of Organic Chemistry|January 23, 2008
Facile synthesis of two diastereomeric indolizidines corresponding to the postulated structure of alkaloid 5,9E-259B from a Bufonid toad (Melanophryniscus)Angela Nelson, H Martin Garraffo, Thomas F Spande, et al.
Journal of Clinical Epidemiology|January 21, 2026
Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trialsAngela Nelson, Hannah Moyer, Karine Vigneault, et al.
Journal of Clinical Epidemiology|April 7, 2023
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trialsHannah Moyer, Merlin Bittlinger, Angela Nelson, et al.
Pageof 1